In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Bavarian Nordic and PowderJect in vaccine delivery alliance

Executive Summary

PowderJect Technologies Ltd. (needle-free injection systems) has invested $2.23mm (DKR18mm) for a 5.6% stake in Danish gene/cell therapy company Bavarian Nordic AS through the purchase of 200k common shares at $10.64 each, a 17% premium over closing price on the day the deal was announced.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Biotechnology
    • Gene Therapy, Cell Therapy
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • Intra-Biotech Deal
    • Manufacturing or Supply
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register